Philipp Ruile1, Nikolaus Jander2, Philipp Blanke3, Simon Schoechlin2, Jochen Reinöhl4, Michael Gick2, Juergen Rothe2, Mathias Langer5, Jonathon Leipsic3, Heinz-Joachim Buettner2, Franz-Josef Neumann2, Gregor Pache5. 1. Department of Cardiology and Angiology II, University Heart Center Freiburg-Bad Krozingen, Südring 15, 79189, Bad Krozingen, Germany. philipp.ruile@universitaets-herzzentrum.de. 2. Department of Cardiology and Angiology II, University Heart Center Freiburg-Bad Krozingen, Südring 15, 79189, Bad Krozingen, Germany. 3. Center for Heart Valve Innovation, St. Paul's Hospital and University of British Columbia, Vancouver, Canada. 4. Department of Cardiology and Angiology I, University Heart Center Freiburg-Bad Krozingen, Bad Krozingen, Germany. 5. Department of Radiology, Section of Cardiovascular Radiology, University of Freiburg, Freiburg im Breisgau, Germany.
Abstract
BACKGROUND: After transcatheter aortic valve implantation, early leaflet thickening, presumably reflecting thrombus, has recently been described on computed tomography angiography (CTA) in ~10% of the patients. We sought to investigate the impact of the antithrombotic regimen on the course of leaflet thickening. METHODS: The study comprised 51 patients with leaflet thickening. Based on the time period, patients without an established indication for anticoagulation were put on phenprocoumon plus clopidogrel for at least 3 months or on dual antiplatelet therapy with aspirin and clopidogrel. Follow-up CTAs were evaluated for leaflet restriction, assessed by four-point-grading score, and maximal thickness. FINDINGS: The anticoagulation and the dual antiplatelet therapy group comprised 29 and 22 patients, respectively. After a median of 86 days, we obtained follow-up CTAs in 22 patients on anticoagulation and in 16 patients on dual antiplatelet therapy. Leaflet thickening progressed in 11 on dual antiplatelet therapy, but always regressed onanticoagulation. The course of leaflet restriction and maximal thickness was significantly different between the two groups (P < 0.001): in the dual antiplatelet therapy group, maximal thickness increased by a mean of 1.37 ± 1.67 mm (P = 0.005) and leaflet restriction score by a median 1[quartiles 0;2] (P = 0.013), whereas in the anticoagulation group, maximal thickness regressed by 2.57 ± 1.52 mm (P < 0.001) and leaflet restriction score decreased by 1[-4;0] (P = 0.001). After a median of 91 days after discontinuation of anticoagulation, CTA performed in ten patients revealed a significant recurrent increase in leaflet restriction score and maximal thickness (P = 0.023, P = 0.007). In the entire cohort, changes in leaflet restriction correlated significantly with changes in transvalvular pressure gradients (r = 0.511, P < 0.001). INTERPRETATION: The course of leaflet restriction was fundamentally different depending on the presence or absence of anticoagulation, with consistent regression under phenprocoumon, but mostly progression under antiplatelet therapy alone. Changes in leaflet restriction were associated with changes in transvalvular pressure gradients.
BACKGROUND: After transcatheter aortic valve implantation, early leaflet thickening, presumably reflecting thrombus, has recently been described on computed tomography angiography (CTA) in ~10% of the patients. We sought to investigate the impact of the antithrombotic regimen on the course of leaflet thickening. METHODS: The study comprised 51 patients with leaflet thickening. Based on the time period, patients without an established indication for anticoagulation were put on phenprocoumon plus clopidogrel for at least 3 months or on dual antiplatelet therapy with aspirin and clopidogrel. Follow-up CTAs were evaluated for leaflet restriction, assessed by four-point-grading score, and maximal thickness. FINDINGS: The anticoagulation and the dual antiplatelet therapy group comprised 29 and 22 patients, respectively. After a median of 86 days, we obtained follow-up CTAs in 22 patients on anticoagulation and in 16 patients on dual antiplatelet therapy. Leaflet thickening progressed in 11 on dual antiplatelet therapy, but always regressed onanticoagulation. The course of leaflet restriction and maximal thickness was significantly different between the two groups (P < 0.001): in the dual antiplatelet therapy group, maximal thickness increased by a mean of 1.37 ± 1.67 mm (P = 0.005) and leaflet restriction score by a median 1[quartiles 0;2] (P = 0.013), whereas in the anticoagulation group, maximal thickness regressed by 2.57 ± 1.52 mm (P < 0.001) and leaflet restriction score decreased by 1[-4;0] (P = 0.001). After a median of 91 days after discontinuation of anticoagulation, CTA performed in ten patients revealed a significant recurrent increase in leaflet restriction score and maximal thickness (P = 0.023, P = 0.007). In the entire cohort, changes in leaflet restriction correlated significantly with changes in transvalvular pressure gradients (r = 0.511, P < 0.001). INTERPRETATION: The course of leaflet restriction was fundamentally different depending on the presence or absence of anticoagulation, with consistent regression under phenprocoumon, but mostly progression under antiplatelet therapy alone. Changes in leaflet restriction were associated with changes in transvalvular pressure gradients.
Authors: Edgar L W Tay; Ronen Gurvitch; Namal Wijeysinghe; Fabian Nietlispach; David Wood; Mike Allard; Brad Munt; Anson Cheung; John G Webb Journal: EuroIntervention Date: 2011-05 Impact factor: 6.534
Authors: Kevin L Greason; Verghese Mathew; Maurice E Sarano; Joseph J Maleszewski; Rakesh M Suri; Charanjit S Rihal Journal: J Card Surg Date: 2013-04-01 Impact factor: 1.620
Authors: Nicolaj C Hansson; Erik L Grove; Henning R Andersen; Jonathon Leipsic; Ole N Mathiassen; Jesper M Jensen; Kaare T Jensen; Philipp Blanke; Tina Leetmaa; Mariann Tang; Lars R Krusell; Kaj E Klaaborg; Evald H Christiansen; Kim Terp; Christian J Terkelsen; Steen H Poulsen; John Webb; Hans Erik Bøtker; Bjarne L Nørgaard Journal: J Am Coll Cardiol Date: 2016-08-28 Impact factor: 24.094
Authors: A Pieter Kappetein; Stuart J Head; Philippe Généreux; Nicolo Piazza; Nicolas M van Mieghem; Eugene H Blackstone; Thomas G Brott; David J Cohen; Donald E Cutlip; Gerrit-Anne van Es; Rebecca T Hahn; Ajay J Kirtane; Mitchell W Krucoff; Susheel Kodali; Michael J Mack; Roxana Mehran; Josep Rodés-Cabau; Pascal Vranckx; John G Webb; Stephan Windecker; Patrick W Serruys; Martin B Leon Journal: Eur Heart J Date: 2012-10 Impact factor: 29.983
Authors: Sorin V Pislaru; Imad Hussain; Patricia A Pellikka; Joseph J Maleszewski; Richard D Hanna; Hartzell V Schaff; Heidi M Connolly Journal: Eur J Cardiothorac Surg Date: 2014-05-14 Impact factor: 4.191
Authors: D Duerschmied; J Brachmann; H Darius; N Frey; H A Katus; W Rottbauer; A Schäfer; H Thiele; C Bode; Uwe Zeymer Journal: Clin Res Cardiol Date: 2018-04-20 Impact factor: 5.460
Authors: Manuel Hein; Jan Minners; Nikolaus Jander; Philipp Breitbart; Christian Stratz; Gregor Pache; Franz-Josef Neumann; Philipp Ruile Journal: Clin Res Cardiol Date: 2019-02-06 Impact factor: 5.460
Authors: Nicolas A Geis; Christina Kiriakou; Emmanuel Chorianopoulos; Lorenz Uhlmann; Hugo A Katus; Raffi Bekeredjian Journal: Clin Res Cardiol Date: 2018-04-11 Impact factor: 5.460